A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths versus placebo https://bit.ly/35Xs1Rf

Detalles Bibliográficos
Autores principales: Singh, Dave, Bogus, Maxim, Moskalenko, Valentyn, Lord, Robert, Moran, Edmund J., Crater, Glenn D., Bourdet, David L., Pfeifer, Nathan D., Woo, Jacky, Kaufman, Elad, Lombardi, David A., Weng, Emily Y., Nguyen, Tuan, Woodcock, Ashley, Haumann, Brett, Saggar, Rajeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859971/
https://www.ncbi.nlm.nih.gov/pubmed/34210790
http://dx.doi.org/10.1183/13993003.00673-2021
_version_ 1784654570789535744
author Singh, Dave
Bogus, Maxim
Moskalenko, Valentyn
Lord, Robert
Moran, Edmund J.
Crater, Glenn D.
Bourdet, David L.
Pfeifer, Nathan D.
Woo, Jacky
Kaufman, Elad
Lombardi, David A.
Weng, Emily Y.
Nguyen, Tuan
Woodcock, Ashley
Haumann, Brett
Saggar, Rajeev
author_facet Singh, Dave
Bogus, Maxim
Moskalenko, Valentyn
Lord, Robert
Moran, Edmund J.
Crater, Glenn D.
Bourdet, David L.
Pfeifer, Nathan D.
Woo, Jacky
Kaufman, Elad
Lombardi, David A.
Weng, Emily Y.
Nguyen, Tuan
Woodcock, Ashley
Haumann, Brett
Saggar, Rajeev
author_sort Singh, Dave
collection PubMed
description The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths versus placebo https://bit.ly/35Xs1Rf
format Online
Article
Text
id pubmed-8859971
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-88599712022-02-22 A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19 Singh, Dave Bogus, Maxim Moskalenko, Valentyn Lord, Robert Moran, Edmund J. Crater, Glenn D. Bourdet, David L. Pfeifer, Nathan D. Woo, Jacky Kaufman, Elad Lombardi, David A. Weng, Emily Y. Nguyen, Tuan Woodcock, Ashley Haumann, Brett Saggar, Rajeev Eur Respir J Agora The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths versus placebo https://bit.ly/35Xs1Rf European Respiratory Society 2021-10-14 /pmc/articles/PMC8859971/ /pubmed/34210790 http://dx.doi.org/10.1183/13993003.00673-2021 Text en Copyright ©The authors 2021. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Agora
Singh, Dave
Bogus, Maxim
Moskalenko, Valentyn
Lord, Robert
Moran, Edmund J.
Crater, Glenn D.
Bourdet, David L.
Pfeifer, Nathan D.
Woo, Jacky
Kaufman, Elad
Lombardi, David A.
Weng, Emily Y.
Nguyen, Tuan
Woodcock, Ashley
Haumann, Brett
Saggar, Rajeev
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
title A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
title_full A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
title_fullStr A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
title_full_unstemmed A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
title_short A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
title_sort phase 2 multiple ascending dose study of the inhaled pan-jak inhibitor nezulcitinib (td-0903) in severe covid-19
topic Agora
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859971/
https://www.ncbi.nlm.nih.gov/pubmed/34210790
http://dx.doi.org/10.1183/13993003.00673-2021
work_keys_str_mv AT singhdave aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT bogusmaxim aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT moskalenkovalentyn aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT lordrobert aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT moranedmundj aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT craterglennd aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT bourdetdavidl aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT pfeifernathand aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT woojacky aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT kaufmanelad aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT lombardidavida aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT wengemilyy aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT nguyentuan aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT woodcockashley aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT haumannbrett aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT saggarrajeev aphase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT singhdave phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT bogusmaxim phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT moskalenkovalentyn phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT lordrobert phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT moranedmundj phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT craterglennd phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT bourdetdavidl phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT pfeifernathand phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT woojacky phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT kaufmanelad phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT lombardidavida phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT wengemilyy phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT nguyentuan phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT woodcockashley phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT haumannbrett phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19
AT saggarrajeev phase2multipleascendingdosestudyoftheinhaledpanjakinhibitornezulcitinibtd0903inseverecovid19

Ejemplares similares